Commentary on “Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813”

<span class="paragraphSection">I have read with great interest the paper entitled "Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813" by Chang et al.^{<a href="#CIT0001" class="reflinks">1</a>} The authors evaluated overall survival (OS) of patients with anaplastic astrocytoma (AA) treated with radiotherapy (RT) and either temozolomide (TMZ) or a nitrosourea (NU), and secondary endpoints were time to tumor progression (TTP), toxicity, and the effect of <span style="font-style:italic;">IDH1</span> mutation status on clinical outcome. The Authors evidenced that out of 103 patients in which isocitrate dehydrogenase 1 (IDH1) status could be determined by immunohistochemistry, 54 patients were <span style="font-style:italic;">IDH</span> negative and 49 were <span style="font-style:italic;">IDH</span> positive, with a better OS in <span style="font-style:italic;">IDH</span>-positive patients. Furthermore RT + TMZ did not appear to significantly improve OS or TTP for AA compared with RT + NU.</span>

from Cancer via ola Kala on Inoreader http://ift.tt/2qZeeE0
via IFTTT